Suppr
超能文献

非住院高危成年人中 SARS-CoV-2 抗病毒药物的开具缺口。

SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults.

机构信息

Helix, San Mateo, California, USA.

HealthPartners Institute, Minneapolis, Minnesota, USA.

出版信息

Clin Infect Dis. 2024 Jun 14;78(6):1531-1535. doi: 10.1093/cid/ciad796.

DOI:10.1093/cid/ciad796

PMID:38170452

Abstract

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

摘要

在一项多州临床队列研究中，我们评估了 2022 年 4 月至 2023 年 6 月期间患有 SARS-CoV-2 且具有 COVID-19 重症风险因素的非住院患者的 SARS-CoV-2 抗病毒药物处方模式。在 3247 名成年人中，仅有 31.9%（87.6%为 nirmatrelvir/ritonavir，11.9%为 molnupiravir，0.5%为 remdesivir）开具了抗病毒药物，这突出表明需要识别和解决治疗障碍。